NO341573B1 - Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen - Google Patents
Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifenInfo
- Publication number
- NO341573B1 NO341573B1 NO20064262A NO20064262A NO341573B1 NO 341573 B1 NO341573 B1 NO 341573B1 NO 20064262 A NO20064262 A NO 20064262A NO 20064262 A NO20064262 A NO 20064262A NO 341573 B1 NO341573 B1 NO 341573B1
- Authority
- NO
- Norway
- Prior art keywords
- ospemifene
- preparation
- solid formulations
- stereoisomer
- metabolite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse vedrører faste medikamentformuleringer omfattende granulater inneholdende ospemifen (også kjent som (deaminohydroksy)toremifen) som en terapeutisk aktiv forbindelse, eller en geometrisk isomer, en stereoisomer, et farmasøytisk akseptabelt salt, en ester derav eller en metabolitt derav, i kombinasjon med én eller flere intra-granulære eksepienser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,024 US8642079B2 (en) | 2004-02-23 | 2004-02-23 | Solid formulations of ospemifene |
PCT/FI2005/000037 WO2005079777A1 (en) | 2004-02-23 | 2005-01-19 | Solid formulations of ospemifene |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20064262L NO20064262L (no) | 2006-09-20 |
NO341573B1 true NO341573B1 (no) | 2017-12-04 |
Family
ID=34861126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064262A NO341573B1 (no) | 2004-02-23 | 2006-09-20 | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen |
Country Status (19)
Country | Link |
---|---|
US (2) | US8642079B2 (no) |
EP (2) | EP1718288B1 (no) |
JP (1) | JP4993203B2 (no) |
CN (1) | CN1953741B (no) |
AT (1) | ATE506054T1 (no) |
AU (1) | AU2005215174B2 (no) |
BR (1) | BRPI0507897B8 (no) |
CA (1) | CA2554695C (no) |
CY (1) | CY1111689T1 (no) |
DE (1) | DE602005027540D1 (no) |
DK (1) | DK1718288T3 (no) |
ES (1) | ES2364970T3 (no) |
MX (1) | MXPA06009546A (no) |
NO (1) | NO341573B1 (no) |
PL (1) | PL1718288T3 (no) |
PT (1) | PT1718288E (no) |
RU (2) | RU2423113C2 (no) |
SI (1) | SI1718288T1 (no) |
WO (1) | WO2005079777A1 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7867516B2 (en) | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
PT1742618E (pt) | 2004-05-04 | 2012-10-11 | Hormos Medical Ltd | Formulações líquidas orais de ospemifeno |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
KR20080075157A (ko) * | 2005-11-09 | 2008-08-14 | 호르모스 메디칼 리미티드 | 피스페미펜 제제 |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
JP5363344B2 (ja) | 2007-02-14 | 2013-12-11 | ホルモス メディカル リミテッド | 治療に有用なトリフェニルブテン誘導体の調製方法 |
MX2010010383A (es) * | 2008-04-01 | 2010-12-14 | Ocean 1 806 Llc | Formulaciones orodispersables de inhibidores de fosfodiesterasa-5 (pde-5). |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
CN104788300B (zh) * | 2014-01-22 | 2017-01-11 | 南京华威医药科技开发有限公司 | 欧司哌米芬多晶型 |
US20160000732A1 (en) * | 2014-07-02 | 2016-01-07 | Cadila Healthcare Limited | Oral pharmaceutical compositions of ospemifene |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
WO2016110805A1 (en) * | 2015-01-09 | 2016-07-14 | Glenmark Pharmaceuticals Limited | Process for preparation of ospemifene |
CN107529758B (zh) * | 2015-03-10 | 2021-01-26 | 盐野义制药公司 | 固体分散体 |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
EP3573472A1 (en) * | 2017-01-24 | 2019-12-04 | Omnigen Research, L.L.C. | Granulated feed supplement and methods for making and using |
BR112022023307A2 (pt) | 2020-05-18 | 2022-12-20 | Orexo Ab | Composição farmacêutica para entrega de fármacos |
EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996007402A1 (en) * | 1994-09-07 | 1996-03-14 | Orion-Yhtymä Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6245252B1 (en) * | 1995-11-14 | 2001-06-12 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117121A (en) | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5597582A (en) | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
FI101305B (fi) | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa |
DE19653736C2 (de) * | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
RU2112504C1 (ru) * | 1996-12-24 | 1998-06-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Средство для лечения заболеваний предстательной железы "витапрост" |
JP2002521322A (ja) * | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
AU2002235348A1 (en) | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
RU2177802C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения |
US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
JP2003137814A (ja) | 2001-08-10 | 2003-05-14 | Takeda Chem Ind Ltd | GnRHアゴニストの併用剤 |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
RU2317816C2 (ru) | 2002-06-06 | 2008-02-27 | Хормос Медикал Корпорейшн | Способ ингибирования атрофии или лечения или предупреждения симптомов, родственных атрофии, у женщин |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
WO2006052921A2 (en) | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
EA200700760A1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
RU2430733C2 (ru) * | 2009-10-08 | 2011-10-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) |
-
2004
- 2004-02-23 US US10/783,024 patent/US8642079B2/en active Active
-
2005
- 2005-01-19 SI SI200531330T patent/SI1718288T1/sl unknown
- 2005-01-19 DE DE602005027540T patent/DE602005027540D1/de active Active
- 2005-01-19 CA CA2554695A patent/CA2554695C/en active Active
- 2005-01-19 MX MXPA06009546A patent/MXPA06009546A/es active IP Right Grant
- 2005-01-19 DK DK05708125.9T patent/DK1718288T3/da active
- 2005-01-19 AT AT05708125T patent/ATE506054T1/de active
- 2005-01-19 PL PL05708125T patent/PL1718288T3/pl unknown
- 2005-01-19 WO PCT/FI2005/000037 patent/WO2005079777A1/en active Application Filing
- 2005-01-19 PT PT05708125T patent/PT1718288E/pt unknown
- 2005-01-19 AU AU2005215174A patent/AU2005215174B2/en active Active
- 2005-01-19 CN CN2005800049727A patent/CN1953741B/zh active Active
- 2005-01-19 EP EP05708125A patent/EP1718288B1/en active Active
- 2005-01-19 BR BRPI0507897A patent/BRPI0507897B8/pt not_active IP Right Cessation
- 2005-01-19 RU RU2006133902/15A patent/RU2423113C2/ru active
- 2005-01-19 ES ES05708125T patent/ES2364970T3/es active Active
- 2005-01-19 EP EP10180718A patent/EP2286806A1/en not_active Withdrawn
- 2005-01-19 RU RU2011112362A patent/RU2675624C2/ru not_active Application Discontinuation
- 2005-01-19 JP JP2007500233A patent/JP4993203B2/ja active Active
-
2006
- 2006-09-20 NO NO20064262A patent/NO341573B1/no unknown
-
2011
- 2011-07-14 CY CY20111100689T patent/CY1111689T1/el unknown
-
2014
- 2014-01-30 US US14/168,842 patent/US20140220118A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996007402A1 (en) * | 1994-09-07 | 1996-03-14 | Orion-Yhtymä Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6245252B1 (en) * | 1995-11-14 | 2001-06-12 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Non-Patent Citations (1)
Title |
---|
GENNARO A.R. "Remington: The Science and Practice of Pharmacy, 20th Ed., Chapter 45, article RUDNIC E.M. "Oral Solid Dosage Forms", s. 858-871, xp002987340, Dated: 01.01.0001 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0507897A (pt) | 2007-07-24 |
CY1111689T1 (el) | 2015-10-07 |
JP4993203B2 (ja) | 2012-08-08 |
CN1953741B (zh) | 2011-03-30 |
PT1718288E (pt) | 2011-07-25 |
DE602005027540D1 (de) | 2011-06-01 |
CN1953741A (zh) | 2007-04-25 |
NO20064262L (no) | 2006-09-20 |
RU2006133902A (ru) | 2008-03-27 |
SI1718288T1 (sl) | 2011-09-30 |
AU2005215174B2 (en) | 2010-06-03 |
DK1718288T3 (da) | 2011-08-01 |
EP1718288A1 (en) | 2006-11-08 |
PL1718288T3 (pl) | 2011-10-31 |
BRPI0507897B8 (pt) | 2021-05-25 |
JP2007523210A (ja) | 2007-08-16 |
EP1718288B1 (en) | 2011-04-20 |
MXPA06009546A (es) | 2007-04-10 |
US20050187301A1 (en) | 2005-08-25 |
ATE506054T1 (de) | 2011-05-15 |
WO2005079777A1 (en) | 2005-09-01 |
CA2554695A1 (en) | 2005-09-01 |
US20140220118A1 (en) | 2014-08-07 |
RU2423113C2 (ru) | 2011-07-10 |
BRPI0507897B1 (pt) | 2018-10-09 |
EP2286806A1 (en) | 2011-02-23 |
RU2675624C2 (ru) | 2018-12-21 |
RU2011112362A (ru) | 2012-10-10 |
US8642079B2 (en) | 2014-02-04 |
CA2554695C (en) | 2013-03-05 |
ES2364970T3 (es) | 2011-09-19 |
AU2005215174A1 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
HUS1500030I1 (hu) | Eljárás az ospemifene biohasznosulásának javítására | |
NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
NO20043367L (no) | Oralt farmasoytisk preparat | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2007084728A3 (en) | 2-imino-benzimidazoles | |
DK1820506T3 (da) | Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf | |
WO2007099410A3 (en) | Formulations of fispemifene | |
DK1678162T3 (da) | P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne | |
TW200800984A (en) | New compounds | |
NO20083183L (no) | Fast farmasoytisk sammensetning inneholdende irbesartan | |
WO2004098594A3 (en) | Dosage form containing pantoprazole as active ingredient | |
WO2006079077A3 (en) | Use of diltiazem or analogs thereof as modulators of ghrelin receptor | |
WO2005120518A3 (en) | Use of atp analogues for treatment of cardiovascular diseases | |
MX2007015171A (es) | Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable. | |
WO2004098577A3 (en) | Dosage form containing (s)-pantoprazole as active ingredient | |
WO2007047881A3 (en) | Method for treating neuropathic pain | |
WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine | |
NO20065074L (no) | Nye orale formuleringer av ospemifen. | |
CY1115013T1 (el) | Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll |